Cellestia Biotech AG presented the first clinical data of its lead compound CB-103 at the virtual congress of the European Society for Medical Oncology (ESMO).
To read Cellestia’s press release click here.
Cellestia Biotech AG presented the first clinical data of its lead compound CB-103 at the virtual congress of the European Society for Medical Oncology (ESMO).
To read Cellestia’s press release click here.
Previous news